Search research articles
Contact Us
Filters
Showing results (131-140 of 146) with videos related to
Page
of 15
Sort By:
European Urology
|
September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
October 16, 2025
Pediatric PET/MRI: Imaging Techniques, Indications, and Clinical Implementation
Sergios Gatidis, Maria Rosana Ponisio, Lise Borgwardt, et al.
European Journal of Epidemiology
|
August 21, 2020
Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis
Petek Eylul Taneri, Sergio Alejandro Gómez-Ochoa, Erand Llanaj, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
Investigative Ophthalmology & Visual Science
|
December 2, 2024
Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies
Melissa A Calton, Roxanne H Croze, Christian Burns, et al.
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
European Urology Oncology
|
May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N Chi, Elena Castro, Gert Attard, et al.
Journal of Managed Care & Specialty Pharmacy
|
July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
Matthew R Smith, Shahneen Sandhu, Daniel J George, et al.
Journal of Biomolecular Screening
|
February 17, 2012
Lead discovery for microsomal prostaglandin E synthase using a combination of high-throughput fluorescent-based assays and RapidFire mass spectrometry
Melanie V Leveridge, Ana Isabel Bardera, William LaMarr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 146) with videos related to
Sort By:
Page
of 15
European Urology
|
September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
Dana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
October 16, 2025
Pediatric PET/MRI: Imaging Techniques, Indications, and Clinical Implementation
Sergios Gatidis, Maria Rosana Ponisio, Lise Borgwardt, et al.
European Journal of Epidemiology
|
August 21, 2020
Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis
Petek Eylul Taneri, Sergio Alejandro Gómez-Ochoa, Erand Llanaj, et al.
Cancer Chemotherapy and Pharmacology
|
March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
Fred Saad, Kim N Chi, Neal D Shore, et al.
Investigative Ophthalmology & Visual Science
|
December 2, 2024
Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies
Melissa A Calton, Roxanne H Croze, Christian Burns, et al.
The Lancet. Oncology
|
February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
Matthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
European Urology Oncology
|
May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N Chi, Elena Castro, Gert Attard, et al.
Journal of Managed Care & Specialty Pharmacy
|
July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
Matthew R Smith, Shahneen Sandhu, Daniel J George, et al.
Journal of Biomolecular Screening
|
February 17, 2012
Lead discovery for microsomal prostaglandin E synthase using a combination of high-throughput fluorescent-based assays and RapidFire mass spectrometry
Melanie V Leveridge, Ana Isabel Bardera, William LaMarr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Kim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Page
of 15